A total of 244 RA sufferers were recruited for this trial across 29 medical trial sites in Poland, Romania, Bulgaria and the Czech Republic. ‘Completion of Element enrolment is a critical milestone in the development of vidofludimus and ensures we are on track to see the Phase IIb final result in RA because of this novel, oral inhibitor of IL-17 discharge,’ said Ulrich Dauer, CEO of 4SC AG. ‘Through the concentrated initiatives of physicians and patients we have jointly had the opportunity to explore the efficacy of vidofludimus in a big population of RA sufferers on MTX background and look forwards to presenting the info in 2011.’ The recently announced exploratory Stage IIa ENTRANCE trial of vidofludimus in inflammatory bowel disease met the primary endpoint and attained a response rate of 88 percent in Crohn’s disease and ulcerative colitis sufferers..Serum antibodies against the identified peptide were also not detected in serum specimens from the sufferers with the two systemic autoimmune diseases that people studied . The sensitivity and specificity of the quantitative analysis of our assay, with a cutoff value of 32,000 international units, were 95 percent and 97 percent, respectively. The AUC in the ROC analysis was 0.988 . By comparing only individuals with autoimmune pancreatitis with sufferers with pancreatic tumor, the sensitivity and specificity were 95 percent and 90 percent, respectively, with an AUC in the ROC evaluation of 0.973 .